Clinical trials: Hypothalamic Diseases
Cushing's Disease
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
This study provided access to pasireotide sc in patients with Cushing's disease.and provided additional information for safety and efficacy of pasireotide s.c.
- Trial name
- SEASCAPE (NCT01582061)
- Testing
- Pasireotide sub-cutaneous
- Where
- 65 sites in United States, Brazil and 9 more
- Volunteers
- 104 people
- Sponsor
- Novartis Pharmaceuticals
Cushing's Disease
Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)
RATIONALE: Rosiglitazone may help pituitary tumor cells become more like normal cells, and to grow and spread more slowly. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with newly…
- Trial name
- NCT00612066
- Testing
- rosiglitazone maleate
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Dwarfism, Pituitary
Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®
This is an open-label, prospective, multicentric, non-comparative, non-randomized Phase IV interventional study in which subjects pre-diagnosed with Growth Hormone Deficiency (GHD) were treated for 4 weeks with Saizen to compare…
- Trial name
- NCT01187550
- Testing
- Recombinant human growth hormone (r-hGH)
- Volunteers
- 214 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Pancreatic Neoplasm, Pituitary Neoplasm
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.
- Conditions
- Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome
- Trial name
- NCT00958841
- Testing
- pasireotide LAR
- Where
- 42 sites in United States, Argentina and 10 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Pituitary Tumors
Barrow Nasal Inventory Survey
The purpose of this study is to evaluate patient nasal outcome following endo-nasal surgery. This type of surgery is conducted for pituitary and skull base tumors.
- Trial name
- BNI (NCT01322945)
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Acromegaly
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
The patients received either Pasireotide LAR or Octreotide LAR for one year of treatment. The objective of this study was to compare the proportion of patients with a reduction of mean GH level to <2.5 µg/L and the normalization…
- Trial name
- NCT00600886
- Testing
- Pasireotide, Octreotide
- Where
- 95 sites in United States, Argentina and 25 more
- Volunteers
- 358 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Non Interventional Study For Patients Treated With Somavert®
This open-label, national, prospective, observational, non-interventional, multi-center, post marketing surveillance study was performed in order to examine the efficacy and safety of Somavert® in treatment of subjects with…
- Trial name
- GPOS (NCT00858143)
- Testing
- Non Interventional Observation
- Volunteers
- 311 people
- Sponsor
- Pfizer
Parkinson's Disease, Hyperprolactinemia
The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events
To assess the association between cabergoline and other dopamine agonists (DAs), and symptomatic, diagnosed serious cardiopulmonary disorders, including: 1. Cardiac valve regurgitation 2.
- Trial name
- NCT01052948
- Testing
- Retrospective study-
- Volunteers
- 86,939 people
- Sponsor
- Pfizer
Brain Tumor, Central Nervous System Tumor
Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma
RATIONALE: Drugs used in chemotherapy, such as carboplatin, vincristine, and temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00077207
- Testing
- carboplatin, temozolomide, vincristine sulfate
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Children's Oncology Group
Kidney Failure, Chronic, Growth Hormone Deficiency
A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood
Treatment with growth hormone (GH; a hormone made by the body that stimulates growth) has been shown to be helpful in treating children with chronic kidney disease who fail to grow.
- Trial name
- NCT00212758
- Testing
- Nutropin AQ
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- Oregon Health and Science University
Acromegaly
Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
MYCAPSSA™ (formerly Octreolin™) is a proprietary oral form of the approved injectable medical product octreotide used to treat acromegaly.
- Trial name
- NCT01412424
- Testing
- Octreotide capsules
- Where
- 36 sites in United States, Germany and 11 more
- Volunteers
- 155 people
- Sponsor
- Chiasma, Inc.
Endogenous Cushing's Syndrome
Treatment for Endogenous Cushing's Syndrome
The primary objectives of this study are to evaluate the clinical responder rate, defined as the proportion of subjects with normal UFC after 6 months of treatment with COR-003 in the Maintenance Phase without dose increase, and…
- Trial name
- SONICS (NCT01838551)
- Testing
- Levoketoconazole
- Where
- 42 sites in United States, Belgium and 13 more
- Volunteers
- 94 people
- Sponsor
- Cortendo AB
Asthma
Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma
Inhaled corticosteroids (ICS) have a number of known class effects including hypothalamic-pituitary-adrenocortical (HPA) axis suppression.
- Trial name
- NCT02483975
- Testing
- FF, Montelukast, Albuterol/Salbutamol
- Where
- 17 sites in United States, South Africa
- Volunteers
- 111 people
- Sponsor
- GlaxoSmithKline
Adult Growth Hormone Deficiency
An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)
This is an open-label, single-arm, multicenter, Phase 4 study to explore the immunogenicity of the liquid formulation of Saizen® in subjects with Adult Growth Hormone Deficiency (AGHD), who are growth hormone (GH) treatment-naïve…
- Trial name
- NCT01806298
- Testing
- Saizen® solution for injection (referred as Saizen®)
- Where
- 19 sites in Australia, Germany and 2 more
- Volunteers
- 78 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Cushing's Disease
Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
The purpose of this study was to confirm efficacy and safety of osilodrostat for the treatment of patients with Cushing's disease who are candidates for medical therapy.
- Trial name
- LINC-4 (NCT02697734)
- Testing
- osilodrostat
- Where
- 36 sites in United States, Belgium and 12 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Cushing's Syndrome
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Participants in study C-1073-400 (NCT00569582) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome.
- Trial name
- NCT00936741
- Testing
- mifepristone
- Where
- 15 sites in United States
- Volunteers
- 30 people
- Sponsor
- Corcept Therapeutics
Acromegaly
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
The purpose of this study is to determine whether subjects with acromegaly (or their partners) are able to self administer Somatuline Autogel at home.
- Trial name
- SALSA (NCT00447499)
- Testing
- Somatuline Autogel (lanreotide acetate), Home administration
- Where
- 13 sites in United States
- Volunteers
- 59 people
- Sponsor
- Ipsen
Gliosis, Obesity
Does What You Eat Affect Your Brain
The purpose of this study is to use magnetic resonance imaging (MRI) to evaluate the human hypothalamus for signs of inflammation in response to specific diets.
- Conditions
- Gliosis, Obesity, Eating
- Trial name
- WYE (NCT05626907)
- Testing
- Diet modification #1, Diet modification #2, Diet modification #3
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Washington
Acromegaly
A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly
The purpose of this study was to determine the safety, tolerability, and efficacy of IONIS-GHR-LRx subcutaneous (SC) injection as monotherapy in patients with acromegaly.
- Trial name
- NCT04522180
- Testing
- GHR-LRX
- Where
- 22 sites in United States, Estonia and 8 more
- Volunteers
- 34 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
This phase II trial studies how well cilengitide works in treating younger patients with recurrent or progressive high-grade glioma that has not responded to standard therapy.
- Conditions
- Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma
- Trial name
- NCT00679354
- Testing
- cilengitide, laboratory biomarker analysis, pharmacological study
- Where
- 20 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)